Vimseltinib approved in the UK for adults with tenosynovial giant cell tumours

Дата публикации: 14-08-2026 15:37:31

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved vimseltinib, marketed as Romvizma, as a new treatment option for adults living with tenosynovial giant cell tumour (TGCT).
The post Vimseltinib approved in the UK for adults with tenosynovial giant cell tumours appeared first on Open Access Government.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	A new treatment has been approved for extensive-stage small cell lung cancer	0	7.66	24-09-2026
2	New NHS approval creates new hope for patients with rare blood cancers	0	6.31	17-07-2026
3	NHS rolls out pembrolizumab for women with advanced cervical cancer	0	6.27	25-06-2026
4	New national cancer board launched to create improvements in cancer care	0	5.1	21-09-2026
5	Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer	0	9.74	24-08-2026
6	FDA approves Welireg-Lenvima combination for advanced RCC	0	10.87	24-09-2026
7	Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps	0	11.04	15-12-2025
8	The NHS has invited 500,000 men to join prostate cancer research	0	7.91	03-08-2026
9	WHO opens new pathway to child-friendly cancer medicines	0	10.49	07-09-2026
10	Tiny RNA pathway emerges as a powerful lever for the future of stem cell therapy	0	8.73	07-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5.27. Источник: www.openaccessgovernment.org.